Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462280 · ClinicalTrials.gov registry record · Phase 2
Lovastatin in Treating Patients At High Risk of Melanoma
A Phase 2 study of Precancerous Condition and Stage II Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT00462280 is a Phase 2 study of Precancerous Condition and Stage II Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 617-participant average among 15 other Precancerous Condition trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00462280, a Phase 2 study of Precancerous Condition and Stage II Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treating patients at high risk of melanoma.
Conditions Studied
Interventions
- OTHER placebo
- PROCEDURE biopsy
- DRUG lovastatin
- PROCEDURE laboratory biomarker analysis
Study Locations (3)
California
- University of California Medical Center At Irvine-Orange Campus - Orange
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462280
The ClinicalTrials.gov registry entry for NCT00462280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 617-participant average among 15 other Precancerous Condition trials with a reported enrollment target (87% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Precancerous Condition appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00462280 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Utah.
Frequently Asked Questions
What is clinical trial NCT00462280 about?
NCT00462280 is a clinical study titled "Lovastatin in Treating Patients At High Risk of Melanoma". The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treati...
What is the current status of trial NCT00462280?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2007-05. Estimated completion is 2012-02.
What conditions does trial NCT00462280 study?
This clinical trial studies the following conditions: Precancerous Condition, Stage II Melanoma, Stage 0 Melanoma, Stage I Melanoma.
What interventions are being tested in trial NCT00462280?
The interventions under investigation include: placebo (OTHER), biopsy (PROCEDURE), lovastatin (DRUG), laboratory biomarker analysis (PROCEDURE).
Who is sponsoring clinical trial NCT00462280?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00462280 being conducted?
This trial has 3 study locations across California, Florida, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Precancerous Condition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
COMPLETED · Phase 2
-
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
COMPLETED · Phase 2
-
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
COMPLETED · Phase 2
-
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
COMPLETED · Phase 2
-
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RECRUITING
-
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.